FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Dr. Charles Ryan carefully reviews the many sequences that exist in the treatment of prostate cancer, with his presentation, entitled, Sequencing and Combining CRPC Therapies: What Does the Future Hold? Dr. Ryan describes the CRPC patient population as a broad-spectrum of disease patterns, and thus the importance to recognize the principles of personalizing CRPC management. He reviews AR targeting in CRPC which provides the opportunity for clinical benefit with relatively low morbidity; however, resistance patterns will emerge via different routes of pathophysiology and thus are drivers of changes in tumor biology, requiring a nimbler approach toward therapeutic strategies. Dr. Ryan also discusses the role for tissue biopsies of metastases as well as “liquid biopsies” or ctDNA, which will assuredly impact future clinical evaluation and treatment decision making.
Concluding this month’s issue is extensive coverage from Société Internationale d’Urologie (SIU) Congress 2017 held in October in Lisbon, Portugal, where a number of compelling abstracts were presented from genitourinary experts worldwide including Martin Gleave’s Optimal Sequencing and Monitoring of Androgen Receptor (AR) Pathway Inhibitors in mCRPC.
We greatly appreciate your support for Everyday Urology, and we look forward to bringing you the latest in hot topics, emerging treatments and expert opinions from our colleagues around the world throughout 2018.